Drug Trial Radar · NCT02876835
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Last checked: Nov 19, 2026Latest source record: Apr 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,872
Actual
Start
Sep 27, 2016
Primary completion
Apr 19, 2021
Study completion Apr 19, 2021
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 24, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
Conditions
- Anaemia
Interventions
DaprodustatDrug
The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.
Darbepoetin alfaDrug
The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.
PlaceboDrug
Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
Iron TherapyDrug
Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)Time frame: Up to 4.3 person-years for CV follow-up time period
- Mean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52)Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)
Locations
574 sites in 39 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Andalusia, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Glendale, Arizona
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Azusa, California
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Chula Vista, California
GSK Investigational Site
Cudahy, California
GSK Investigational Site
El Centro, California
GSK Investigational Site
Escondido, California
GSK Investigational Site
Glendale, California
GSK Investigational Site
Granada Hills, California
GSK Investigational Site
La Mesa, California
GSK Investigational Site
La Palma, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Montebello, California
GSK Investigational Site
National City, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Luis Obispo, California
GSK Investigational Site
Simi Valley, California
GSK Investigational Site
Tarzana, California
GSK Investigational Site
Whittier, California
GSK Investigational Site
Middlebury, Connecticut
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Boca Raton, Florida
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Cutler Bay, Florida
GSK Investigational Site
Doral, Florida
GSK Investigational Site
Fort Lauderdale, Florida
Showing 40 of 574 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.